Vivek Subbiah: Second Annual Virtual Summit on AI in Precision Oncology
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Thrilled to announce I’ll be joining an exceptional panel at the Second Annual Virtual Summit on AI in Precision Oncology this December!
Amazing vision by Douglas Flora, for spearheading this summit on AI and Precision Oncology.
Looking forward to the fireside chat with the terrific Sanjay Juneja, as we explore the transformative potential for AI in precision oncology and drug development.
Join us for dynamic keynotes, engaging panel discussions, and thought-provoking fireside chats with leading oncology experts as well as luminaries in AI.
Plenty of valuable insights and forward-looking perspectives from who’s who in the AI and oncology world.
Thursday, December 12, 2024
8:00 am PT | 11:00 am ET | 17:00 CET.”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.
He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023